About us Get involved Research COVAX Marketplace News & stories Careers Contact Creating a world in which epidemics are no longer a threat to humanity CEPI is an innovative global partnership between public, private, philanthropic, and civil society organisations launched in Davos in 2017 to develop vaccines to stop future epidemics. Our mission is to accelerate the development of vaccines against emerging infectious diseases and enable equitable access to these vaccines for people during outbreaks. OUR MISSION OUR APPROACH New vaccines for a safer world As the COVID-19 pandemic shows, in a world characterised by increasing population density, human mobility, and ecological change, emerging infectious diseases (EIDs) pose a real and growing threat to global health security. Epidemic diseases affect us all. They do not respect borders. The costs of EIDs are vast, in both human and economic terms. As well as the devastating death toll and disruption to societies, COVID-19 could cost the global economy $4.1 trillion, or almost 5% of global gross domestic product. Even small epidemics can cause tremendous economic disruption. Vaccines are one of our most powerful tools in the fight to outsmart epidemics. The development of vaccines can help save lives, protect societies and restabilise economies. The Coalition for Epidemic Preparedness Innovations’ (CEPI’s) mission is to stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks. Scientist harvesting flu virus The challenge Historically, vaccine development has been a long, risky, and costly endeavour. Planning for emerging infectious diseases is especially challenging: the market potential for vaccines against these diseases is limited and testing such vaccines is difficult. We need a better system to speed the development of vaccines against emerging infectious diseases. Events like the devastating 2014/15 outbreak of Ebola in West Africa—which killed more than 11,000 people and had an economic and social burden of over $53 billion—showed us that very few vaccines are ready to be used against these threats. The world’s response to this crisis fell tragically short. A vaccine that had been under development for more than a decade was not deployed until over a year into the epidemic. That vaccine was shown to be 100% effective, suggesting that much of the epidemic could have been prevented. The creation of CEPI The Coalition for Epidemic Preparedness Innovations (CEPI) was launched at Davos 2017 as the result of a consensus that a coordinated, international, and intergovernmental plan was needed to develop and deploy new vaccines to prevent future epidemics. We are an innovative global partnership between public, private, philanthropic, and civil society organisations working to accelerate the development of vaccines against emerging infectious diseases and enable equitable access to these vaccines for affected populations during outbreaks. Close collaboration with global partners are crucial to ensure the success of our work. Therefore, we will support coordinating activities to improve our collective response to epidemics, strengthening capacity in countries at risk, and advancing the regulatory science that governs product development. Launch of CEPI at Davos, 2017 Strengthening global health security Many organisations operate within the end-to-end space of vaccine funding and R&D implementation. However, a number of critical gaps have been identified, which CEPI was designed to fill. First, CEPI will advance vaccines against known threats through proof-of-concept and safety testing in humans and will establish investigational vaccine stockpiles before epidemics begin—”just in case”. Second, we will fund new and innovative platform technologies with the potential to accelerate the development and manufacture of vaccines against previously unknown pathogens (eg: within 16 weeks from identification of antigen to product release for clinical trials)—”just in time”. Third, CEPI will support and coordinate activities to improve our collective response to epidemics, strengthen capacity in countries at risk, and advance the regulatory science that governs product development. PREPAREDNESS RESPONSE SUSTAINABILITY Advance access to safe and effective vaccines against emerging infectious diseases A global coalition CEPI is an innovative partnership between public, private, philanthropic, and civil organisations launched to develop vaccines to stop future epidemics. Our headquarters are in Oslo, Norway, and we have offices in London, UK, and Washington DC, USA. We also work closely with public-sector, private-sector, and civil-society partners around the world. BECOME A PARTNER A sustainable partnership Our global coalition is ambitious both in its scope and in the breadth of organisations involved. CEPI takes an end-to-end approach, operating as both a funder and a facilitator. We focus on vaccine development, licensure, and manufacturing while supporting the efforts of our partners in vaccine discovery and delivery. A coordinated, international, and intergovernmental response is needed to respond to the global threat posed by emerging infectious disease. Therefore, close collaboration with our global partners will be crucial to the success of our work to develop vaccines against these diseases. CEPI role as a facilitator CEPI role as a funder 1 DISCOVERY 2 DEVELOPMENT / LICENSURE 3 MANUFACTURE 4 DELIVERY / STOCKPILING 5 LAST MILE Academia Governments Wellcome Trust NIH IMI GLOPID-R Industry Regulators Biotech Industry Governments Regulators Wellcome Trust NIH EC IMI BMGF BARDA/DTRA etc. WHO Biotech PDPs Industry BARDA CMOs Regulators Governments WHO GHIF GAVI UNICEF PAHO Governments WHO Industry Pandemic Emergency Facility (World Bank) WHO Contingency Fund Countries WHO UNICEF Responding Organisations (eg, MSF) BARDA: Biomedical Advanced Research and Development Authority CMOs: Contract Manufacturing Organisations DTRA: Defense Threat Reduction Agency EC: European Commission GAVI: Global Alliance for Vaccines and Immunisation GHIF: Global Health Investment Fund GLOPID-R: Global Research Collaboration for Infectious Disease Preparedness IMI: Innovative Medicines Initiative MSF: Médecins Sans Frontières NIH: National Institutes of Health PAHO: Pan American Health Organization PDPs: Product Development Partnerships UNICEF: United Nations Children's Fund WHO: World Health Organisation GET INVOLVED Key milestones OUR MISSION OUR APPROACH ABOUT US Why we exist Mission Approach Who we are Overview Leadership Board Investors & Partners Scientific Advisory Committee Joint Coordination Group Antiracism statement Anti-Slavery Statement Governance Articles of association Board Meeting Summaries Board of Directors' report, annual accounts and Auditor's statement Business Plan CEPI Policies Equitable Access Financial Internal policies Investors Council Joint Coordination Group Members Meetings Other Guidance for Awardees Scientific Advisory Committee Strategy & Progress Terms of reference GET INVOLVED Support CEPI Invest in CEPI Progress Work with CEPI Work at CEPI Follow our work Calls for Proposals RESEARCH & DEVELOPMENT Our portfolio Platform Technology Priority diseases MERS Lassa Nipah Disease X Rift Valley fever Chikungunya Ebola Vaccine science Biological Standards, Assays & Animal Models Collect vaccine data Researching emerging infectious diseases INFO & ACTION News & stories Outbreaks Careers Contact Social LinkedIn Twitter Legal Terms of use Privacy policy Procurement tenders Reporting Concern ©2021 CEPI. All rights reserved